News stories about Adverum Biotechnologies (NASDAQ:ADVM) have trended somewhat positive this week, according to Accern Sentiment Analysis. The research firm rates the sentiment of media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Adverum Biotechnologies earned a news sentiment score of 0.15 on Accern’s scale. Accern also assigned headlines about the biotechnology company an impact score of 46.3381029678595 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
These are some of the headlines that may have impacted Accern Sentiment Analysis’s scoring:
- Worldwide Juvenile Macular Degeneration Market is Estimated to Grow at a CAGR of 6.7% till 2023 (consumerelectronicsnet.com)
- Friedreich Ataxia Market Key Players – Adverum Biotechnologies Inc, Biovista Inc, and Ixchel Pharma LLC Analysis & Forecast 2018 to 2022 (newsmaker.com.au)
- Brokerages Expect Adverum Biotechnologies Inc (ADVM) Will Announce Earnings of -$0.31 Per Share (americanbankingnews.com)
- Adverum Biotechnologies (ADVM) Downgraded by BidaskClub to Buy (americanbankingnews.com)
- Adverum Biotechnologies Inc (ADVM) Receives Average Recommendation of “Hold” from Analysts (americanbankingnews.com)
Several analysts have recently issued reports on the company. BidaskClub cut Adverum Biotechnologies from a “strong-buy” rating to a “buy” rating in a research note on Saturday. Piper Jaffray Companies assumed coverage on Adverum Biotechnologies in a research note on Thursday, February 15th. They issued an “overweight” rating and a $12.00 price objective on the stock. ValuEngine upgraded Adverum Biotechnologies from a “strong sell” rating to a “sell” rating in a research note on Thursday, January 25th. Zacks Investment Research upgraded Adverum Biotechnologies from a “sell” rating to a “hold” rating in a research note on Tuesday, January 9th. Finally, Chardan Capital restated a “hold” rating on shares of Adverum Biotechnologies in a research note on Tuesday, December 19th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the company. Adverum Biotechnologies presently has a consensus rating of “Hold” and an average target price of $6.06.
Adverum Biotechnologies (NASDAQ:ADVM) last posted its quarterly earnings results on Tuesday, March 6th. The biotechnology company reported ($0.32) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.35) by $0.03. Adverum Biotechnologies had a negative return on equity of 29.61% and a negative net margin of 3,036.61%. The company had revenue of $0.46 million for the quarter. research analysts forecast that Adverum Biotechnologies will post -1.31 EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “Adverum Biotechnologies (ADVM) Receiving Somewhat Favorable News Coverage, Study Shows” was reported by BBNS and is the sole property of of BBNS. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of United States and international copyright law. The original version of this piece can be viewed at https://baseballnewssource.com/2018/03/14/adverum-biotechnologies-advm-receiving-somewhat-favorable-news-coverage-study-shows/2027216.html.
Adverum Biotechnologies Company Profile
Adverum Biotechnologies, Inc is a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases. Adverum has a robust pipeline that includes product candidates designed to treat rare diseases alpha-1 antitrypsin (A1AT) deficiency and hereditary angioedema (HAE) as well as wet age-related macular degeneration (wAMD).
Receive News & Ratings for Adverum Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adverum Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.